Vignesh Raman1, Oliver K Jawitz2, Chi-Fu Jeffrey Yang3, Soraya L Voigt2, Thomas A D'Amico2, David H Harpole2, Betty C Tong2. 1. Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, NC. Electronic address: vignesh.raman@duke.edu. 2. Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, NC. 3. Department of Cardiothoracic Surgery, Stanford University Medical Center, Stanford, Calif.
Abstract
BACKGROUND: There is poor understanding of the comparative effectiveness of lobar and sublobar resections for limited-stage small cell lung cancer (SCLC). We analyzed the National Cancer Database to examine the outcomes of patients undergoing wedge resection (WR), segmentectomy (SR), and lobectomy (LB) for limited-stage SCLC. METHODS: Patients with cT1-2N0M0 SCLC (2004-2015) who underwent definitive surgery were identified and stratified by extent of resection: WR, SR, or LB. The primary outcome was overall survival (OS) and secondary outcomes were margin-positive resection (>R0) and pathologic nodal upstaging. RESULTS: A total 1948 patients met study criteria: 619 (32%) underwent WR, 96 (5%) SR, and 1233 (63%) LB. Patients receiving LB were more likely to be younger, have fewer comorbidities, and be privately insured. The unadjusted 5-year OS of WR, SR, and LB patients was 31% (95% confidence interval [CI], 27-35), 35% (95% CI, 25-49), and 45% (95% CI, 42-49), respectively. In a multivariable Cox model, WR was associated with worse OS (hazard ratio, 1.53; 95% CI, 1.31-1.79) and SR similar OS (hazard ratio, 1.20; 95% CI, 0.87-1.67) compared with LB. SR was associated with similar survival compared with LB in a propensity score-matched multivariable analysis as well. WR was also associated with greater odds of >R0 resection compared with LB. CONCLUSIONS: In this study, patients with limited-stage SCLC undergoing WR experienced worse survival compared with those undergoing LB; survival was similar between segmentectomy and LB.
BACKGROUND: There is poor understanding of the comparative effectiveness of lobar and sublobar resections for limited-stage small cell lung cancer (SCLC). We analyzed the National Cancer Database to examine the outcomes of patients undergoing wedge resection (WR), segmentectomy (SR), and lobectomy (LB) for limited-stage SCLC. METHODS: Patients with cT1-2N0M0 SCLC (2004-2015) who underwent definitive surgery were identified and stratified by extent of resection: WR, SR, or LB. The primary outcome was overall survival (OS) and secondary outcomes were margin-positive resection (>R0) and pathologic nodal upstaging. RESULTS: A total 1948 patients met study criteria: 619 (32%) underwent WR, 96 (5%) SR, and 1233 (63%) LB. Patients receiving LB were more likely to be younger, have fewer comorbidities, and be privately insured. The unadjusted 5-year OS of WR, SR, and LB patients was 31% (95% confidence interval [CI], 27-35), 35% (95% CI, 25-49), and 45% (95% CI, 42-49), respectively. In a multivariable Cox model, WR was associated with worse OS (hazard ratio, 1.53; 95% CI, 1.31-1.79) and SR similar OS (hazard ratio, 1.20; 95% CI, 0.87-1.67) compared with LB. SR was associated with similar survival compared with LB in a propensity score-matched multivariable analysis as well. WR was also associated with greater odds of >R0 resection compared with LB. CONCLUSIONS: In this study, patients with limited-stage SCLC undergoing WR experienced worse survival compared with those undergoing LB; survival was similar between segmentectomy and LB.
Authors: Matthew J Schuchert; Brian L Pettiford; Samuel Keeley; Thomas A D'Amato; Arman Kilic; John Close; Arjun Pennathur; Ricardo Santos; Hiran C Fernando; James R Landreneau; James D Luketich; Rodney J Landreneau Journal: Ann Thorac Surg Date: 2007-09 Impact factor: 4.330
Authors: Peter Paximadis; Jennifer L Beebe-Dimmer; Julie George; Anne G Schwartz; Antoinette Wozniak; Shirish Gadgeel Journal: Clin Lung Cancer Date: 2018-03-23 Impact factor: 4.785
Authors: Susan E Combs; Jacquelyn G Hancock; Daniel J Boffa; Roy H Decker; Frank C Detterbeck; Anthony W Kim Journal: J Thorac Oncol Date: 2015-02 Impact factor: 15.609
Authors: Nasser K Altorki; Xiaofei Wang; Dennis Wigle; Lin Gu; Gail Darling; Ahmad S Ashrafi; Rodney Landrenau; Daniel Miller; Moishe Liberman; David R Jones; Robert Keenan; Massimo Conti; Gavin Wright; Linda J Veit; Suresh S Ramalingam; Mohamed Kamel; Harvey I Pass; John D Mitchell; Thomas Stinchcombe; Everett Vokes; Leslie J Kohman Journal: Lancet Respir Med Date: 2018-11-12 Impact factor: 30.700